Cytotoxic agents in sarcoidosis: Which one should we choose?

Current Opinion in Pulmonary Medicine

Volumn 20, Issue 5, 2014, Pages 479-487

  Vorselaars, Adriane D M ^a   Cremers, Johanna P ^b,c   Grutters, Jan C ^a,d   Drent, Marjolein ^b,e  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b GELDERSE VALLEI HOSPITAL   (Netherlands)

^c Sittard Geleen Heerlen   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

biologicals; cytotoxic drugs; immunosuppresion; sarcoidosis; therapy

Indexed keywords

CYTOTOXIN; IMMUNOSUPPRESSIVE AGENT; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

ANTAGONISTS AND INHIBITORS; HUMAN; SARCOIDOSIS;

CYTOTOXINS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SARCOIDOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84906053862     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000078     Document Type: Review

References (94)

1. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 1997; 336:1224-1234.
2. Judson MA, Baughman RP, Thompson BW, et al. Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20:204-211.
3. Judson M.A. An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment. Chest 1999; 115:1158-1165.
4. Sharma OP. Pulmonary sarcoidosis and corticosteroids. Am Rev Respir Dis 1993; 147:1598-1600.
5. Selroos O. Treatment of sarcoidosis. Sarcoidosis 1994; 11:80-83.
6. Paramothayan S, Jones PW. Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. J Am Med Assoc 2002; 287:1301-1307.
7. Grutters JC, van den Bosch JM. Corticosteroid treatment in sarcoidosis. Eur Respir J 2006; 28:627-636.
8. Paramothayan NS, Lasserson TJ, Jones PW. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev 2005; CD001114.
9. Gibson GJ, Prescott RJ, Muers MF, et al. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax 1996; 51:238-247.
10. Reich JM. Corticosteroid therapy and relapse in sarcoidosis. Chest 1998; 113:559-561.
11. Vorselaars AD, van Moorsel CH, Deneer VH, Grutters JC. Current therapy in sarcoidosis, the role of existing drugs and future medicine. Inflamm Allergy Drug Targets 2013; 12:369-377.
12. Cronstein B. How does methotrexate suppress inflammation? Clin Exp Rheumatol 2010; 28:S21-S23.
13. Hasko G, Cronstein B. Regulation of inflammation by adenosine. Front Immunol 2013; 4:85.
14. Schutt AC, Bullington WM, Judson M.A. Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Respir Med 2010; 104:717-723.
15. Cremers JP, Drent M, Bast A, et al. Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommen dations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. Curr Opin Pulm Med 2013; 19:545-561.
16. Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000; 17:60-66.
17. Vorselaars AD, Wuyts WA, Vorselaars VM, et al. Methotrexate versus azathioprine in second line therapy of sarcoidosis. Chest 2013; 144:805-812.
18. Baughman RP, Lower EE, Ingledue R, Kaufman AH. Management of ocular sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2012; 29:26-33.
19. Vucinic VM. What is the future of methotrexate in sarcoidosis? A study and review. Curr Opin Pulm Med 2002; 8:470-476.
20. Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 1995; 155:846-851.
21. Lower EE, Broderick JP, Brott TG, Baughman RP. Diagnosis and management of neurological sarcoidosis. Arch Intern Med 1997; 157:1864-1868.
22. Isshiki T, Yamaguchi T, Yamada Y, et al. Usefulness of low-dose methotrexate monotherapy for treating sarcoidosis. Intern Med 2013; 52:2727-2732.
23. Conway R, Low C, Coughlan RJ, et al. Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum 2013. doi: 10.1002/art.38322. [Epub ahead of print]
24. Pacheco Y, Marechal C, Marechal F, et al. Azathioprine treatment of chronic pulmonary sarcoidosis. Sarcoidosis 1985; 2:107-113.
25. Muller-Quernheim J, Kienast K, Held M, et al. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 1999; 14:1117-1122.
26. Lewis SJ, Ainslie GM, Bateman ED. Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16:87-92.
27. Baughman RP, Lower EE. Alternatives to corticosteroids in the treatment of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1997; 14:121-130.
28. Bakker JA, Drent M, Bierau J. Relevance of pharmacogenetic aspects of mercaptopurine metabolism in the treatment of interstitial lung disease. Curr Opin Pulm Med 2007; 13:458-463.
29. Dong XW, Zheng Q, Zhu MM, et al. Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease. World J Gastroenterol 2010; 16:3187-3195.
30. Fox RI, Herrmann ML, Frangou CG, et al. How does leflunomide modulate the immune response in rheumatoid arthritis? Bio Drugs 1999; 12:301-315.
31. Majithia V, Sanders S, Harisdangkul V, Wilson JG. Successful treatment of sarcoidosis with leflunomide. Rheumatology (Oxford) 2003; 42:700-702.
32. Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21:43-48.
33. Sahoo DH, Bandyopadhyay D, Xu M, et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J 2011; 38:1145-1150.
34. Lee SW, Park HJ, Kim BK, et al. Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate. Arthritis Res Ther 2012; 14:R232.
35. Baughman RP, Nunes H, Sweiss NJ, Lower EE. Established and experimental medical therapy of pulmonary sarcoidosis. Eur Respir J 2013; 41:1424-1438.
36. Bird P, Griffiths H, Tymms K, et al. The SMILE study: safety of methotrexate in combination with leflunomide in rheumatoid arthritis. J Rheumatol 2013; 40:228-235.
37. Siltzbach LE, Teirstein AS. Chloroquine therapy in 43 patients with intra-thoracic and cutaneous sarcoidosis. Acta Med Scand Suppl 1964; 425:302-308.
38. Baltzan M, Mehta S, Kirkham TH, Cosio MG. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med 1999; 160:192-197.
39. Sharma OP. Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement. Arch Neurol 1998; 55:1248-1254.
40. Jones E, Callen JP. Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. J Am Acad Dermatol 1990; 23:487-489.
41. Sweiss NJ, Patterson K, Sawaqed R, et al. Rheumatologic manifestations of sarcoidosis. Semin Respir Crit Care Med 2010; 31:463-473.
42. Brill AK, Ott SR, Geiser T. Effect and safety of mycophenolate mofetil in chronic pulmonary sarcoidosis: a retrospective study. Respiration 2012; 86:376-383.
43. Androdias G, Maillet D, Marignier R, et al. Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy. Neurology 2011; 76:1168-1172.
44. Zaidi AA, Devita MV, Michelis MF, Rosenstock JL. Mycophenolate mofetil as a steroid-sparing agent in sarcoid-associated renal disease. Clin Nephrol 2013. [Epub ahead of print]
45. Bhat P, Cervantes-Castaneda RA, Doctor PP, et al. Mycophenolate mofetil therapy for sarcoidosis-associated uveitis. Ocul Immunol Inflamm 2009; 17:185-190.
46. Kouba DJ, Mimouni D, Rencic A, Nousari HC. Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis. Br J Dermatol 2003; 148:147-148.
47. Arai M, Sugiura A. Chronic relapsing demyelinating polyneuropathy associated with sarcoidosis: successful treatment with intravenous pulse cyclo-phosphamide. Intern Med 2001; 40:1261-1262.
48. Demeter SL. Myocardial sarcoidosis unresponsive to steroids. Treatment with cyclophosphamide. Chest 1988; 94:202-203.
49. Israel RH, Poe RH. Massive pericardial effusion in sarcoidosis. Respiration 1994; 61:176-180.
50. Bradley DA, Lower EE, Baughman RP. Diagnosis and management of spinal cord sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23:58-65.
51. Doty JD, Mazur JE, Judson M.A. Treatment of corticosteroid-resistant neuro-sarcoidosis with a short-course cyclophosphamide regimen. Chest 2003; 124:2023-2026.
52. Poormoghim H, Moradi Lakeh M, Mohammadipour M, et al. Cyclophospha-mide for scleroderma lung disease: a systematic review and meta-analysis. Rheumatol Int 2012; 32:2431-2444.
53. Korsten P, Mirsaeidi M, Sweiss NJ. Nonsteroidal therapy of sarcoidosis. Curr Opin Pulm Med 2013; 19:516-523.
54. Ye Q, Chen B, Tong Z, et al. Thalidomide reduces IL-18, IL-8 and TNF-alpha release from alveolar macrophages in interstitial lung disease. Eur Respir J 2006; 28:824-831.
55. Nguyen YT, Dupuy A, Cordoliani F, et al. Treatment of cutaneous sarcoidosis with thalidomide. J Am Acad Dermatol 2004; 50:235-241.
56. Carlesimo M, Giustini S, Rossi A, et al. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995; 32:866-869.
57. Baughman RP, Judson MA, Teirstein AS, et al. Thalidomide for chronic sarcoidosis. Chest 2002; 122:227-232.
58. Judson MA, Silvestri J, Hartung C, et al. The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23:51-57.
59. Fazzi P, Manni E, Cristofani R, et al. Thalidomide for improving cutaneous and pulmonary sarcoidosis in patients resistant or with contraindications to corticosteroids. Biomed Pharmacother 2012; 66:300-307.
60. Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997; 155:1665-1669.
61. Park MK, Fontana J, Babaali H, et al. Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26:121-131.
62. Baughman RP, Judson MA, Ingledue R, et al. Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. Arch Dermatol 2012; 148:262-264.
63. Ziegenhagen MW, Rothe ME, Zissel G, Muller-Quernheim J. Exaggerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoi-dosis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19:185-190.
64. Denys BG, Bogaerts Y, Coenegrachts KL, De Vriese AS. Steroid-resistant sarcoidosis: is antagonism of TNF-alpha the answer? Clin Sci (Lond) 2007; 112:281-289.
65. Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174:795-802.
66. Rossman MD, Newman LS, Baughman RP, et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23:201-208.
67. Judson MA, Baughman RP, Costabel U, et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 2008; 31:1189-1196.
68. van Rijswijk HN, Vorselaars AD, Ruven HJ, et al. Changes in disease activity, lung function and quality of life in patients with refractory sarcoidosis after anti-TNF treatment. Expert Opin Orphan Drugs 2013; 1:437-443.
69. Elfferich MD, Nelemans PJ, Ponds RW, et al. Everyday cognitive failure in sarcoidosis: the prevalence and the effect of anti-TNF-alpha treatment. Respiration 2010; 80:212-219.
70. Wijnen PA, Cremers JP, Nelemans PJ, et al. Association of the TNF-alpha G-308A polymorphism with TNF-inhibitor response in sarcoidosis. Eur Respir J 2014; 43:1730-1739.
71. Hostettler KE, Studler U, Tamm M, Brutsche MH. Long-term treatment with infliximab in patients with sarcoidosis. Respiration 2012; 83:218-224.
72. Russell E, Luk F, Manocha S, et al. Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy. Semin Arthritis Rheum 2013; 43:119-124.
73. Vorselaars AD, Verwoerd A, van Moorsel CH, et al. Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis. Eur Respir J 2014; 43:602-609.
74. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098-1104.
75. Baughman RP, Lower EE, Drent M. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them. Sarcoidosis Vasc Diffuse Lung Dis 2008; 25:76-89.
76. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64:625-639.
77. Furst DE, Keystone EC, So AK, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis 2013; 72 (Suppl 2:ii):2-34.
78. Kamphuis LS, Lam-Tse WK, Dik WA, et al. Efficacy of adalimumab in chronically active and symptomatic patients with sarcoidosis. Am J Respir Crit Care Med 2011; 184:1214-1216.
79. Judson M.A. Successful treatment of lupus pernio with adalimumab. Arch Dermatol 2011; 147:1332-1333.
80. Erckens RJ, Mostard RL, Wijnen PA, et al. Adalimumab successful in sarcoidosis patients with refractory chronic noninfectious uveitis. Graefes Arch Clin Exp Ophthalmol 2012; 250:713-720.
81. Milman N, Graudal N, Loft A, et al. Effect of the TNF-alpha inhibitor adali-mumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET. Clin Respir J 2012; 6:238-247.
82. Pariser RJ, Paul J, Hirano S, et al. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol 2013; 68:765-773.
83. Drent M, Cremers J, Jansen T, Baughman R. Practical eminence and experience-based recommendations for use of TNF-a inhibitors in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31:91-107.
84. Pouw MF, Krieckaert C L, Nurmohamed M T, et al. Key findings towards optimising adalimumab treatment: the concentration-effect curve. Ann Rheum Dis 2013. doi: 10.1136/annrheumdis-2013-204172. [Epub ahead of print]
85. Kamphuis LS, van Zelm MC, Lam KH, et al. Perigranuloma localization and abnormal maturation of B cells: emerging key players in sarcoidosis? Am J Respir Crit Care Med 2013; 187:406-416.
86. Lower EE, Baughman RP, Kaufman AH. Rituximab for refractory granuloma-tous eye disease. Clin Ophthalmol 2012; 6:1613-1618.
87. Sweiss NJ, Lower EE, Mirsaeidi M, et al. Rituximab in the treatment of refractory pulmonary sarcoidosis. Eur Respir J 2014; 43:1525-1528. The first trial investigating rituximab in sarcoidosis.
88. Beegle SH, Barba K, Gobunsuy R, Judson M.A. Current and emerging pharmacological treatments for sarcoidosis: a review. Drug Des Devel Ther 2013; 7:325-338.
89. Romao VC, Canhao H, Fonseca JE. Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs? BMC Med 2013; 11:17.
90. Seitzer U, Swider C, Stuber F, et al. Tumour necrosis factor alpha promoter gene polymorphism in sarcoidosis. Cytokine 1997; 9:787-790.
91. Kieszko R, Krawczyk P, Chocholska S, et al. TNF-alpha and TNF-beta gene polymorphisms in Polish patients with sarcoidosis. Connection with the susceptibility and prognosis. Sarcoidosis Vasc Diffuse Lung Dis 2010; 27:131-137.
92. Wijnen PA, Nelemans PJ, Verschakelen JA, et al. The role of tumor necrosis factor alpha G-308A polymorphisms in the course of pulmonary sarcoidosis. Tissue Antigens 2010; 75:262-268.
93. Kung TN, Dennis J, Ma Y, et al. RFC-1 80G
94. Wessels JA, de Vries-Bouwstra JK, Heijmans BT, et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleo-tide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum 2006; 54:1087-1095.